Century Therapeutics (IPSC) Income from Continuing Operations (2020 - 2026)
Century Therapeutics (IPSC) reported Income from Continuing Operations of 21665000.0 for Q1 2026, down 128.3% year-over-year from 76560000.0 in Q1 2025, and down 126.93% quarter-over-quarter from 9547000.0 in Q4 2025.
Century Therapeutics (IPSC) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has 7 years of Income from Continuing Operations data on file, last reported at 21665000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 21665000.0, down 128.3% year-over-year; the trailing twelve-month figure through Mar 2026 was 98175000.0 (down 365.81% YoY), and the FY2025 annual result was 39000.0, up 100.03% from the prior year.
- Income from Continuing Operations declined to 21665000.0 in Q1 2026 per IPSC's latest filing, from 9547000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 76560000.0 in Q1 2025 and troughed at 39401000.0 in Q4 2023.
- A 5-year average of 24406352.94 and a median of 31256000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations soared 372.82% in 2025, then tumbled 128.3% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 31677000.0 in 2022, then retreated by 24.38% to 39401000.0 in 2023, then climbed by 10.65% to 35203000.0 in 2024, then surged by 72.88% to 9547000.0 in 2025, then sank by 126.93% to 21665000.0 in 2026.
- Business Quant data shows IPSC's Income from Continuing Operations at 21665000.0 in Q1 2026, 9547000.0 in Q4 2025, and 34422000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Century Therapeutics | 412.10 Mn | 412.10 Mn | - | -21.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.67 Mn |
| Dec 31, 2025 | -9.55 Mn |
| Sep 30, 2025 | -34.42 Mn |
| Jun 30, 2025 | -32.54 Mn |
| Mar 31, 2025 | 76.56 Mn |
| Dec 31, 2024 | -35.20 Mn |
| Sep 30, 2024 | -31.23 Mn |
| Jun 30, 2024 | -31.21 Mn |
| Mar 31, 2024 | -28.06 Mn |
| Dec 31, 2023 | -39.40 Mn |
| Sep 30, 2023 | -32.72 Mn |
| Jun 30, 2023 | -33.29 Mn |
| Mar 31, 2023 | -31.26 Mn |
| Dec 31, 2022 | -31.68 Mn |
| Sep 30, 2022 | -30.75 Mn |
| Jun 30, 2022 | -30.99 Mn |
| Mar 31, 2022 | -37.51 Mn |
| Dec 31, 2021 | -28.15 Mn |
| Sep 30, 2021 | -26.01 Mn |
| Jun 30, 2021 | -23.27 Mn |